Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07766304 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-term Psychological and Cognitive Evaluation of Children Treated With Allogeneic Hematopoietic Stem Cell Transplantation for Immunodeficiency

Study acronym: PSY-DIP
StatusRecruiting
PhaseNot specified
Started2026-09-19
View on ClinicalTrials.gov ↗

Amendment history

2026-09-26
notable
Recruitment opened
Primary immunodeficiencies (PIDs) are a large group of genetic diseases of the immune system with highly variable clinical presentations. Allogeneic hematopoietic stem cell transplantation (HSCT) is one of the treatments offered to some patients with PIDs. It is a curative but particularly demanding treatment, potentially life-threatening, requiring several months of hospitalization, prolonged limitations in social interactions for the patient, and impacting the entire family unit. The short-term complications of HSCT are numerous and well-known. However, few studies describe the long-term psychological and cognitive complications of HSCT, particularly in the context of PIDs. The few published studies in children concern patients transplanted for hematological malignancies, a context very different from that of primary immunodeficiencies. This study is a pilot research project focusing on the multidimensional assessment of the neurocognitive, psychological, and psychosocial functioning of children between 6 and 8 years old who have received allogeneic hematopoietic stem cell transplantation for primary immunodeficiency for at least 2 years. These stringent criteria aim to limit biases related to the diversity of ages at which care is provided.
Trial Details
NCT Number NCT07766304
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Conditions Primary Immunodeficiencies, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Enrollment 30 participants
Start Date 2026-09-19
Primary Completion 2028-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-09-25